FY2025 EPS Estimates for ELDN Boosted by Cantor Fitzgerald

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Investment analysts at Cantor Fitzgerald increased their FY2025 earnings per share estimates for Eledon Pharmaceuticals in a report released on Thursday, May 15th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the company will earn ($0.73) per share for the year, up from their previous estimate of ($1.23). The consensus estimate for Eledon Pharmaceuticals' current full-year earnings is ($0.81) per share.

Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.20.

Separately, Guggenheim assumed coverage on shares of Eledon Pharmaceuticals in a report on Tuesday, January 28th. They issued a "buy" rating and a $9.00 target price on the stock.

Eledon Pharmaceuticals Trading Down 0.7%

Eledon Pharmaceuticals stock opened at $2.87 on Monday. The firm has a market capitalization of $171.86 million, a price-to-earnings ratio of -1.43 and a beta of 0.08. The firm's fifty day moving average price is $3.17 and its two-hundred day moving average price is $3.94. Eledon Pharmaceuticals has a 1-year low of $2.30 and a 1-year high of $5.54.

Institutional Investors Weigh In On Eledon Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Zimmer Partners LP lifted its stake in Eledon Pharmaceuticals by 0.7% during the 1st quarter. Zimmer Partners LP now owns 754,970 shares of the company's stock valued at $2,559,000 after acquiring an additional 4,970 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Eledon Pharmaceuticals by 418.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 7,944 shares of the company's stock valued at $33,000 after purchasing an additional 6,412 shares during the last quarter. CW Advisors LLC bought a new position in shares of Eledon Pharmaceuticals during the first quarter valued at about $34,000. Renaissance Technologies LLC lifted its position in shares of Eledon Pharmaceuticals by 8.3% during the fourth quarter. Renaissance Technologies LLC now owns 147,173 shares of the company's stock valued at $606,000 after purchasing an additional 11,300 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new position in Eledon Pharmaceuticals during the first quarter worth about $41,000. Institutional investors own 56.77% of the company's stock.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.